A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era
SM Pfister, M Reyes-Múgica, JKC Chan, H Hasle… - Cancer discovery, 2022 - AACR
Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …
Implementation of precision medicine in healthcare—A European perspective
A Stenzinger, EK Moltzen, E Winkler… - Journal of Internal …, 2023 - Wiley Online Library
The technical development of high‐throughput sequencing technologies and the parallel
development of targeted therapies in the last decade have enabled a transition from …
development of targeted therapies in the last decade have enabled a transition from …
Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American …
K Manickam, MR McClain, LA Demmer, S Biswas… - Genetics in …, 2021 - nature.com
Purpose To develop an evidence-based clinical practice guideline for the use of exome and
genome sequencing (ES/GS) in the care of pediatric patients with one or more congenital …
genome sequencing (ES/GS) in the care of pediatric patients with one or more congenital …
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme
A Sosinsky, J Ambrose, W Cross, C Turnbull… - Nature Medicine, 2024 - nature.com
Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing
S Newman, J Nakitandwe, CA Kesserwan, EM Azzato… - Cancer discovery, 2021 - AACR
Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-
risk disease. Here, we used a three-platform sequencing approach, including whole …
risk disease. Here, we used a three-platform sequencing approach, including whole …
The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies
P Berlanga, G Pierron, L Lacroix, M Chicard… - Cancer discovery, 2022 - AACR
MAPPYACTS (NCT02613962) is an international prospective precision medicine trial
aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory …
aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory …
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations
A Villani, S Davidson, N Kanwar, WW Lo, Y Li… - Nature Cancer, 2023 - nature.com
We conducted integrative somatic–germline analyses by deeply sequencing 864 cancer-
associated genes, complete genomes and transcriptomes for 300 mostly previously treated …
associated genes, complete genomes and transcriptomes for 300 mostly previously treated …
Benefits for children with suspected cancer from routine whole-genome sequencing
A Hodder, SM Leiter, J Kennedy, D Addy, M Ahmed… - Nature Medicine, 2024 - nature.com
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to
children with cancer and to alter treatment in high-risk patient groups. It remains unknown …
children with cancer and to alter treatment in high-risk patient groups. It remains unknown …
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
The spectrum of germline predisposition in pediatric cancer continues to be realized. Here
we report 751 patients with solid tumors who underwent prospective matched tumor–normal …
we report 751 patients with solid tumors who underwent prospective matched tumor–normal …
Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute–Children's …
DW Parsons, KA Janeway, DR Patton… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The National Cancer Institute–Children's Oncology Group Pediatric MATCH trial
aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts …
aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts …